Advertisement

Current Status of Peritoneal Surface Malignancy in Thailand

  • Chayanit SirisaiEmail author
  • Asada Methasate
Review Article

Abstract

Peritoneal dissemination negatively affects the survival of cancer patients. Comprehensive treatment comprising of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) introduced by Dr. Paul H. Sugarbaker in 1980 has shown a benefit in survival especially in patients with gastrointestinal cancer and ovarian cancer. Thailand started to perform this integrated treatment in 2012. A modification of the heart–lung machine was used as the hyperthermic pump for the first few years. Until now, 240 cases have been treated in 7 centers. Although the Thai health care system covers all areas and is easy to access, many surgeons still doubt the benefit and safety of this treatment. This coupled with difficulty in procuring the equipment, and high procedural cost has resulted in few surgeons offering this treatment and fewer patients availing of it. The small group of peritoneal surface malignancy (PSM) surgeons tries to educate all health care providers to understand how it works in an advanced-stage cancer patient and to make this procedure be covered by the national health care policy.

Keywords

Peritoneal surface Malignancy HIPEC Thailand 

Notes

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Sugarbaker PH (1995) Peritoneal procedure. Annal of Surgery 221(1):29–42CrossRefGoogle Scholar
  2. 2.
    Li Y, Zhou YF, Liang H, Wang HQ, Hao JH, Zhu ZG et al (2016) Chinese expert consensus on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal malignancies. World J Gastroenterol 22(30):6906–6916CrossRefGoogle Scholar
  3. 3.
    Bushat M, Rovers KP, Sommariva A, Sugarbaker PH, Morris DL, Yonemura Y et al (2018) The current practice of cytoreductive surgery and HIPEC for colorectal peritoneal metastases: results of a worldwide web-based survey of the Peritoneal Surface Oncology Group International (PSOGI). In: European journal of surgical oncologyGoogle Scholar
  4. 4.
    Passot G, Bakrin N, Roux AS, Vaudoyer D, Gilly FN, Glehen O et al (2014) Quality of life after cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy: a prospective study of 216 patients. EJSO 40:529–535CrossRefGoogle Scholar
  5. 5.
    WHO (2015) The kingdom of Thailand health system review. WHO Regional Office for the Western Pacific, ManilaGoogle Scholar
  6. 6.
    annual report fiscal year NSHO (2017) National Health Security Office. In: 2018Google Scholar

Copyright information

© Indian Association of Surgical Oncology 2018

Authors and Affiliations

  1. 1.Division of Peritoneal Surface Malignancy, Department of Gastrointestinal SurgeryNational Cancer Institute of ThailandBangkokThailand
  2. 2.Division of Minimal Invasive Surgery, Department of Surgery, Faculty of Medicine, Siriraj HospitalMahidol UniversityBangkokThailand

Personalised recommendations